TABLE 1

Patient Clinical Characteristics

Patient no.	Age (y), sex	Germline mutation	Age at initial diagnosis	Status at the time of ¹⁸F-FLT and ¹⁸F-FDG PET	Size of largest lesion at time of ¹⁸F-FLT/¹⁸F-FDG	Dopamine secretion	Reason for evaluation at time of ¹⁸F-FLT and ¹⁸F-FDG PET	Previous systemic treatments (delay between end of last treatment and PET scan)	2-y follow-up (progression or death from PGL)
1	43, M	Sporadic	43	Primary	3.8 cm	Negative	Suspected primary	None	No
2	43, M	SDHD	43	Primary	4.8 cm	Negative	Suspected primary	None	No
3	43, M	SDHD	41	Primary	4.7 cm	Negative	Restaging	None	No
4	48, F	MEN2	35	Metastatic	12 cm	Negative	Restaging	¹³¹I-metaiodobenzylguanidine (>2 y)	No
5	47, M	Sporadic	30	Metastatic	Unknown	Negative	Suspected recurrence	None	No
6	70, M	Sporadic	67	Metastatic	24 cm	Negative	Suspected recurrence	None	No
7	50, F	Sporadic	43	Metastatic	8 cm	Negative	Restaging	¹³¹I-metaiodobenzylguanidine (8 mo), sandostatin therapy (on)	No
8	30, M	SDHB	30	Primary	2.5 cm	Negative	Initial staging	None	No
9	27, M	SDHB	27	Primary	3 cm	Negative	Initial staging	None	No
10	35, M	SDHB	19	Metastatic	8 cm	Positive	Restaging	None	Yes
11	35, M	SDHB	25	Metastatic	7 cm	Positive	Restaging	CVD (>2 y), ¹³¹I-metaiodobenzylguanidine (4 mo)	Yes
12	47, M	SDHB	41	Metastatic	3 cm	Negative	Restaging	CVD (2 mo)	Yes